Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular...
Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP. This...
Cepheid, a leading molecular diagnostics company, announced today that Vitor Rocha has officially joined the company in the role of President....
Cepheid, a leading molecular diagnostics company, announced today that Vitor Rocha has officially joined the company in the role of President. Rocha...
Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration for Xpert Mpox, which runs on...
Les souches mutantes de la grippe qui circulent actuellement mettent en évidence le besoin de tests de diagnostic multicibles. Deux mutations...
Die derzeit zirkulierenden mutierten Influenzastämme verdeutlichen die Notwendigkeit von Multiziel-Diagnosetests. Zwei kürzlich identifizierte...
Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests. Two recently identified mutations in the...
Cepheid today announced the availability of Xpert® GBS LB XC (extended coverage), a molecular diagnostic test for qualitative detection of Group B...
Cepheid announced today that it has launched Xpert Xpress MVP, a multiplexed PCR test which detects DNA from organisms associated with three distinct ...
Cepheid and BioGX today announced a collaboration between the two companies to deliver a PCR test for Monkeypox that will run on the GeneXpert system....
Cepheid a annoncé aujourd'hui qu'il avait reçu le marquage CE pour Xpert® Xpress CoV-2 plus, un test de diagnostic moléculaire rapide pour la...
Cepheid gibt heute bekannt, dass die Firma die CE-Kennzeichnung für Xpert® Xpress CoV-2 plus erhalten hat, einem diagnostischen PCR-Schnelltest für...
Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress CoV-2...
Cepheid actively monitors COVID-19 virus mutations and is well prepared to support detection of the "Omicron" B.1.1.529 variant with its...
Cepheid a annoncé aujourd'hui avoir reçu le label CE pour Xpert Xpress CoV-2/Flu/RSV plus, un test de diagnostic moléculaire rapide pour la détection ...
Neue „Plus"-Version des Tests fügt ein drittes Gentarget hinzu, um den Nachweis künftiger SARS-CoV-2-Varianten zu verbessern SUNNYVALE, Kalifornien,...
Cepheid anunció hoy que ha recibido la marca CE para Xpert Xpress CoV-2/Gripe/RSV plus, una prueba de diagnóstico molecular rápido para la detección...
Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Xpress...
Today Cepheid announced that it has received CE-IVD clearance for Xpert® HIV-1 Viral Load XC and Xpert® HIV-1 Qual XC, next-generation...
Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress...
Cepheid today announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the...
Cepheid and Sherlock Biosciences today announced a research collaboration between the two companies to explore the development of new cutting-edge...
Cepheid today announced that in response to the rapid outbreak of a new coronavirus strain, the Company is developing an automated molecular test for ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.